BIODEP
BIOmarkers in DEPression (BIODEP) study, Wellcome NIMA consortium
UK multi-centre case-control study of inflammation in major depression: brain MRI (quantitative magnetization transfer, multi-echo resting-state fMRI) of 143 adults aged 25 to 50 stratified by blood CRP, and [11C]PK11195 TSPO PET/MR of 76. No published data sharing route.
Overview
BIODEP is a UK observational case-control study run by the Wellcome Trust Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) consortium, jointly sponsored by Cambridgeshire and Peterborough NHS Foundation Trust and the University of Cambridge (REC 15/EE/0092). It asks whether inflammation marks a subgroup of people with major depression. A primary cohort gave clinical data and blood only. A secondary cohort of depressed cases and healthy controls added brain MRI, and a subset of it also had TSPO PET and, in a few people, lumbar puncture. This entry covers the imaging of the secondary cohort.
Composition
Kitzbichler et al. (2021) report complete data for 143 adults aged 25 to 50: 53 healthy controls, 55 depressed cases with C-reactive protein (CRP) below 3 mg/L and 35 with CRP above 3 mg/L. After MRI quality control, 129 remained (84 women, 45 men; mean age 35.5 years in controls and 37.1 in cases). Cases had a Hamilton depression score above 13 at enrolment and again before scanning. Schubert et al. (2021) describe 76 people with PET: 51 depressed cases (31 low CRP, 20 high CRP) and 25 controls. Participants were recruited in Brighton, Cambridge, Glasgow, London (King's College) and Oxford.
Acquisition
MRI took place at Cambridge, King's College London and Oxford, on Siemens and GE scanners. The protocol included quantitative magnetization transfer (spoiled gradient echo, 10 flip angle and offset combinations, 2.4 x 2.4 x 2.5 mm) and 10.7 minutes of multi-echo resting-state EPI (TE 15, 34 and 54 ms, TR 2.57 s, 250 volumes). PET used 60-minute dynamic [11C]PK11195 acquisitions on a GE SIGNA PET/MR with a simultaneous T1-weighted BRAVO scan. Blood CRP was measured in one central laboratory.
Annotations
No image annotations. Labels are case or control status, CRP group, treatment response and clinical questionnaire scores.
Known limitations
- Not public. No data sharing statement or terms are published; the HRA summary only names a study contact.
- Field strengths and per-site scanner counts are not reported in the sources checked.
- The overlap between the 143 MRI participants and the 76 PET participants is not reported.
- Quantitative MRI could not be harmonised between the Siemens and GE sites, so one site was left out of some analyses.
Cohort
Aggregate numbers from the sources below. Bars are relative to the 143 subjects.
Sex
- Female 84 65%
- Male 45 35%
Covers 129 of 143 subjects.
Modality
subjects
- MRI 143 100%
- PET 76 53%
Contrast / sequence
subjects, values can overlap
- T1-weighted 76 53%
PET tracer
subjects
- [11C]PK11195 76 53%
Condition
subjects, values can overlap
- Major depressive disorder 90 63%
- Healthy control 53 37%
Scanner vendor
subjects
- GE HealthCare 76 53%
Country
subjects
- United Kingdom 143 100%
License and access
Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer
Ask the authors or the data holder. No published process or terms, and access is at their discretion
The NHS Health Research Authority summary names Edward T. Bullmore (University of Cambridge) as the study contact. None of the imaging papers has a statement on access to the data.
No published license or data use terms
The data holder has published no license and no data use terms. Any use, sharing or commercial right has to be agreed with the data holder, and nothing can be assumed to be allowed. Default copyright and data protection law still apply.
The HRA research summary describes the study and its results but gives no data sharing terms. The data availability statement of Kitzbichler et al. (2021) covers only the analysis software, and Schubert et al. (2021) and Althubaity et al. (2022) have none. The study's page on the NIMA consortium website could not be reached.
What you can do
- Commercial use Not stated
- Train ML models Not stated
- Create derived data Not stated
- Publish results Not stated
What you can share
- Share the data Not stated
- Share derived data Not stated
- Share trained models Not stated
What you must do
- Cite or credit Not stated
- Share alike Not stated
- Sign an agreement Not stated
- Ethics approval Not stated
- Manuscript review Not stated
- Release code Not stated
- Return results Not stated
- Delete after use Not stated
Limits
- No re-identification Not stated
- Location limits Not stated
Citation
Kitzbichler MG, Aruldass AR, Barker GJ, Wood TC, Dowell NG, Hurley SA, McLean J, Correia M, Clarke C, Pointon L, Cavanagh J, Cowen P, Pariante C, Cercignani M, Bullmore ET, Harrison NA, NIMA Consortium. Peripheral inflammation is associated with micro-structural and functional connectivity changes in depression-related brain networks. Molecular Psychiatry 26, 7346-7354 (2021). doi:10.1038/s41380-021-01272-1
All numbers
Every number on this page, as stored in stats.csv, with its source.
| Measure | Breakdown | Value | Source |
|---|---|---|---|
| Subjects | total secondary (imaging) cohort participants with complete data; the papers do not give the size of the whole imaging cohort | 143 | kitzbichler2021 Methods: Study design and sample |
| Subjects | modality=MR | 143 | kitzbichler2021 Methods: Study design and sample |
| Subjects | condition=healthy healthy controls with CRP < 3 mg/L | 53 | kitzbichler2021 Methods: Study design and sample |
| Subjects | condition=depression 55 cases with CRP < 3 mg/L and 35 with CRP > 3 mg/L; the two groups are disjoint | 90 | kitzbichler2021 Methods: Study design and sample |
| Subjects | sex=female 27 controls and 57 cases; counted in the 129 participants left after MRI quality control | 84 | kitzbichler2021 Table 1 |
| Subjects | sex=male 19 controls and 26 cases; counted in the 129 participants left after MRI quality control | 45 | kitzbichler2021 Table 1 |
| Subjects | country=GB recruited at Brighton, Cambridge, Glasgow, King's College London and Oxford; scanned at Cambridge, King's College London or Oxford | 143 | kitzbichler2021-si Methods: Study design and sample |
| Subjects | modality=PT [11C]PK11195 PET/MR; the HRA summary describes the PET group as a subset of the imaging cohort, and the papers do not say how many are among the 143 | 76 | schubert2021 Methods: Participants |
| Subjects | tracer=pk11195 51 depressed cases (36 women, 15 men) and 25 healthy controls (14 women, 11 men) | 76 | schubert2021 Methods: Participants |
| Subjects | contrast=T1w T1-weighted BRAVO acquired during PET; T1-weighted counts for the MRI-only participants are not reported | 76 | schubert2021 Methods: TSPO PET Data Acquisition and Analysis |
| Subjects | vendor=ge GE SIGNA PET/MR | 76 | schubert2021 Methods: TSPO PET Data Acquisition and Analysis |
Sources
The keys used in the table above.
- kitzbichler2021 Kitzbichler et al. 2021, Molecular Psychiatry (PMC8872995) paper
- kitzbichler2021-si Kitzbichler et al. 2021, Molecular Psychiatry, Supplementary Information paper
- schubert2021 Schubert et al. 2021, Biological Psychiatry Cognitive Neuroscience and Neuroimaging (PMC8264953) paper
- chamberlain2019 Chamberlain et al. 2019, British Journal of Psychiatry paper
- hra-biodep NHS Health Research Authority research summary, BIOmarkers in DEPression (BIODEP) website